BRAF and central nervous system cancer: A phase II trial has evaluated the use of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib (Figure 2) in children and adolescents with relapsed and refractory BRAF-mutated high-grade glioma (NCT02684058).